0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

CHEMOTHERAPY IN STREPTOCOCCIC INFECTIONS

JAMA. 1937;108(1):48-49. doi:10.1001/jama.1937.02780010050014.
Text Size: A A A
Published online

Since the significant paper of Domagk1 in 1935, renewed interest has developed in the possibility of chemotherapy in streptococcic diseases. A dark red dye synthesized by Mietzsch and Klarer seemed promising in animal protection experiments. The dye is the hydrochloride of 4'-sulfamido-2: 4-diaminoazobenzene. Its toxicity both for mice and for human beings is remarkably slight. In Domagk's report "prontosil," as this dye has been named, was administered by stomach tube to twelve of twenty-six mice an hour and a half after intraperitoneal inoculation with virulent hemolytic streptococci of human origin. All of the twelve that received the dye survived at least seven days. Of the remaining fourteen animals, which served as untreated controls, thirteen were dead within three days and the fourteenth died on the fourth day. Partial corroboration of Domagk's work has been published by Levaditi and Vaisman and considerable suggestive clinical data have been supplied by other

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();